Sensitive PCR-based AML MRD assays have been used for some time to monitor both recurrent translocations including core binding factor leukemias (Yin et al., 2012; Pigazzi et al., 2015; Ouyang et al., 2016; Schumacher et al., 2017) inv(16) and t(8;21) RUNX1-RUNX1T1 and t(15;17) PML-RARA (Burnett et al., 2015; Brunetti et al., 2017) from RNA and can now be detected using multiplex RNAseq NGS-based approaches (Dillon et al., 2019). The gene discussed is RUNX1; the disease is acute myeloid leukemia.